The stem cell therapy market size has grown exponentially in recent years. It will grow from $6.43 billion in 2023 to $7.94 billion in 2024 at a compound annual growth rate (CAGR) of 23.5%. The historical period's growth can be ascribed to an increasing prevalence of chronic diseases, heightened funding from both governmental and private entities, rapid expansion in emerging markets, augmented investments in cell and gene therapies, a surge in healthcare expenditure, and a rise in pharmaceutical research and development expenditure.
The stem cell therapy market size is expected to see rapid growth in the next few years. It will grow to $13.12 billion in 2028 at a compound annual growth rate (CAGR) of 13.4%. The anticipated growth in the forecast period can be attributed to an increase in government support, a rapid rise in the aging population, heightened research and development spending, and a continued increase in healthcare expenditure. Key trends expected in this period involve a focus on closely monitoring advancements in mesenchymal stem cell therapy to leverage innovations in the field. Market players are advised to engage in collaborations and acquisitions to advance product innovation and drive revenues. Furthermore, companies should consider investments in the development of induced pluripotent stem cell (iPSC)-derived natural killer (NK) cells for patient treatment. In the stem cell therapy market, a strategic emphasis on developing therapies, particularly for cancer, can provide a competitive edge over somatic cell competitors. Lastly, companies in the stem cell therapy market are encouraged to harness artificial intelligence to enhance product quality, safety, and manufacturing productivity.
The growth of the stem cell therapy market is significantly influenced by the increasing prevalence of chronic diseases. Factors such as extended working hours, limited physical activity, and unhealthy dietary habits contribute to the rising incidence of chronic diseases, creating a demand for stem cell therapy. According to a United Nations article, it is projected that by 2030, chronic diseases will account for 70% of global deaths. The global burden of chronic diseases is expected to reach approximately 60%, further fueling the growth of the stem cell therapy market.
The expanding field of personalized medicine is poised to drive the future growth of the stem cell therapy market. Personalized medicine, also known as precision medicine, involves tailoring medical treatment plans to account for individual variations in genes, environment, and lifestyle. This approach enhances the effectiveness of stem cell treatments by customizing them based on the unique genetic and medical profiles of individual patients. This not only improves treatment outcomes but also reduces adverse effects, prioritizing patient well-being. The patient-centric nature of personalized medicine, coupled with precise patient selection, more effective clinical trials, and market expansion, contributes to the increasing appeal of stem cell therapies and is expected to propel market growth. For instance, in 2022, the Food and Drug Administration’s Center for Drug Evaluation and Research (CDER) approved 37 new molecular entities (NMEs), with approximately 34% (12 of them) classified as personalized medicines by the Personalized Medicine Coalition (PMC). Consequently, the growing prominence of personalized medicine is a key driver for the expansion of the stem cell therapy market.
Companies within the stem cell therapy market are increasingly engaging in strategic partnerships, representing mutually beneficial agreements between entities that do not directly compete. A notable example is the partnership formed in May 2022 between SQZ Biotechnologies, a US-based biotechnology company, and STEMCELL Technologies Inc., a Canada-based biotechnology company. This collaboration aims to develop and commercialize a research-use-only (RUO) microfluidic intracellular delivery system based on SQZ's Cell Squeeze technology. The partnership is geared towards providing the life sciences community with enhanced cell engineering capabilities for preclinical research. SQZ Biotechnologies and STEMCELL Technologies Inc. are expected to present significant findings demonstrating the potential of the RUO system in efficiently delivering cargoes to primary immune cell types, showcasing advancements in cell engineering with mRNA and CRISPR/Cas9 in hematopoietic stem cells.
Major players in the stem cell therapy market are directing their focus towards the development of innovative technologies, such as Induced Pluripotent Stem Cells (iPSC), to enhance the efficiency of stem cell therapies. iPSCs are derived from blood or skin cells that are reProgramd to an embryonic-such as pluripotent state, offering an unlimited source of various human cells crucial for stem cell therapeutic purposes. An example of this technology is the genome engineering platform for iPSCs launched by Synthego Corporation, a US-based genome engineering company, in October 2022. This platform provides an unprecedented level of editing efficiency for iPSCs on an industrial scale, facilitating precise modifications and creating disease models, including neurodegenerative conditions such as Alzheimer's disease. The platform enables the creation of high-quality, physiologically relevant biological models for translational medicine, promising advancements in research and therapeutic development.
In July 2022, Vertex Pharmaceuticals Inc., a US-based biotechnology company, made a significant acquisition by purchasing ViaCyte Pharma Inc. for $320 million. This acquisition strengthened Vertex Pharmaceuticals' commitment to developing transformative cell replacement therapies for type 1 diabetes. ViaCyte Pharma Inc., a US-based biotechnology company, focuses on innovative stem cell-derived cell replacement therapies, particularly for type 1 diabetes (T1D). The acquisition provided Vertex Pharmaceuticals with additional tools, technologies, stem cell lines, and manufacturing facilities, accelerating their ongoing programs in this field.
Major companies operating in the stem cell therapy market report are Smith & Nephew PLC, Fujifilm Holding Corporation, Thermo Fisher Scientific Inc., Takara Bio Inc., MEDIPOST Co., Ltd., Astellas Pharma Inc., Catalent, Inc., Pharmicell Co., Ltd., JCR Pharmaceuticals Co., Ltd., Stemedica Cell Technologies, Inc., Pluristem Technologies Ltd., Becton Dickinson Private Limited, Stem Cell Technologies India Pvt. Ltd., Cordlife India Pvt. Ltd., Lifecell International Pvt. Ltd., Stemcyte India Therapeutics Private Limited, Stempeutics Research Private Limited, Reelabs Private Limited, Anterogen Co., Ltd., Tonghua Dongbao Pharmaceutical Co, China Biologic Products Holdings Inc., Astrazenaca, Ablbio, Adimmune, Henlius, China Regenerative Medicine International, Innovent Biologics, Bio-Thera, Hisun Pharma, 3sbio, Beijing Shuanglu Pharmaceuticals, Qilu Pharmaceutical, Shanghai Fosun Pharmaceuticals , Cellerix, Cellgenix, Nsgene, Tigenix, Renuron Group, Smart Cells And Genenta Science, Amsterdam Molecular Therapeutics (Amt), Ark Therapeutics, Arthrogen Bv, Diamyd Medical Ab, Oxford Biomedica, Transgene, Mol Med, Selvita, Mabion, Pure Biologics, Oncoarendi Therapeutics, Captor Therapeutics, Celon Pharma, Nanovelos, Dickinson And Company, Sigma Aldrich (A Subsidiary Of Merck Kgaa), Osiris Therapeutics, Capricortherapeutics, Cellular Dynamics Discgenics, Takeda Pharmaceuticals, Kolon Tissue Gene, Athersys, Cyro-Cell International, Geron Corporation, Mesoblast Ltd., Astrom Biosciences Inc., Celgene Corporation, Invitrogen, Cytori Therapeutics Inc., Nuvasive Inc., Bristol-Myers Squibb Aldagen Inc., Caladrius Biosciences Inc., Adcock Ingram, Bayer East Africa Ltd., Biogen Sa, Daiichi Sankyo Co. Ltd., Gamida Cell Ltd., Gilead Sciences, Inc., Novartis Ag, Pfizer, Sanofi.
North America was the largest region in the stem cell therapy market in 2023. The Middle East is expected to be the fastest-growing region in the global stem cell therapy market during the forecast period. The regions covered in the stem cell therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the stem cell therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain.
There are two primary types of stem cell therapy allogeneic stem cell therapy and autologous stem cell therapy. In allogeneic stem cell transplantation, stem cells are sourced from a healthy donor and transferred to the patient's body following intensive chemotherapy or radiation. The cells can be derived from various sources, including adult stem cells, induced pluripotent stem cells, and embryonic stem cells, and are employed in treating conditions such as musculoskeletal disorders, wounds and injuries, cancer, autoimmune disorders, among others. These therapies find application in hospitals and clinics.
The stem cell therapy market research report is one of a series of new reports that provides stem cell therapy market statistics, including stem cell therapy industry global market size, regional shares, competitors with a stem cell therapy market share, detailed stem cell therapy market segments, market trends and opportunities, and any further data you may need to thrive in the stem cell therapy industry. This stem cell therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The stem cell therapy market includes revenues earned by entities by hematopoietic stem cells, skin stem cells, neural stem cells, and mesenchymal stem cells. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
